Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: No evidence of increased risk of liver failure with pioglitazone

Diabetes, Obesity and Metabolism

Volumn 7, Issue 2, 2005, Pages 161-169

  Rajagopalan, R ^a   Iyer, S ^a   Perez, A ^a  

^a TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Antidiabetic drugs; Hepatitis; Hepatotoxicity; Liver failure; Pioglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; EMERGENCY TREATMENT; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; INCIDENCE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONBIOLOGICAL MODEL; RISK ASSESSMENT; TOXIC HEPATITIS;

EID: 14844356009     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00382.x     Document Type: Article

References (26)

1. Neuschwander-Tetri BA, Isley WL, Oki JC, Quiason SG, Phillips NJ, Brunt EM. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med 1998; 129: 38-41.
2. Jagannath S, Rai R. Rapid-onset subfulminant liver failure associated with troglitazone. Ann Intern Med 2000; 132: 677.
3. Murphy EJ, Daver TJ, Shakil AO et al. Troglitazone-induced fulminant hepatic failure. Acute liver failure study group. Dig Dis Sci 2000; 45: 549-553.
4. Kohlroser J, Mathai J, Reichheld J, Baner BF, Bonkovsky HL. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 2000; 95: 272-276.
5. Gouda HE, Khan A, Schwartz J, Cohen RI. Liver failure in a patient treated with long-term rosiglitazone therapy. Am J Med 2001; 111: 584-585.
6. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000; 132: 118-121.
7. Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med 2000; 133: 237.
8. Chase MP, Yarze JC. Pioglitazone-associated fulminant hepatic failure. Am J Gastroenterol 2002; 97: 502-503.
9. May LE, Lefkowitch JH, Kram MT, Rubin DE. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002; 136: 449-452.
10. Rubin CJ, Schneider RL. Pioglitazone liver enzyme profile is similar to placebo in U.S. controlled clinical trials. Diabetes 2000; 49 (Suppl. 1): A123.
11. Lebovitz HE, Salzman A. Rosiglitazone liver safety update. Diabetes 2000; 49 (Suppl. 1): A39.
12. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25: 815-821.
13. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-763.
14. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
15. Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med 2002; 135: 306.
16. Erbey JR, Silberman C, Lydick E. Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med 2000; 109: 588-590.
17. El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002; 122: 1822-1828.
18. Pittas AG, Greenberg AS. Thiazolidinediones in the treatment of Type 2 diabetes. Expert Opin Pharmacother 2002; 3: 529-540.
19. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002; 18: S23-S29.
20. ACTOS Prescribing Information. Lincolnshire, IL: Takeda Pharmaceuticals North America, Inc, 2003 (retrieved from: http://www.actos.com/pi.pdf).
21. Kostrubsky VE, Sinclair JE, Ramachandran V et al. The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures. Drug Metab Dispos 2000; 28: 1192-1197.
22. Elcock FJ, Lyron JJ, Hitchcock J et al. Toxicity of troglitazone in cultures of rat hepatocytes. Diabetes 1999; 48 (Suppl. 1): A63.
23. Lee SM, Cho TS, Kim DJ, Cha YN. Protective effect of ethanol against acetaminophen induced hepatotoxicity in mice. Biochem Pharmacol 1999; 58: 1547-1555.
24. Tolman KG, Chandramouli J. Hepatotoxicity of the thiazolidinediones: Clin Liver Dis 2003; 7: 369-379.
25. Scheen AJ. Hepatotoxicity with thiazolidinediones: Is it a class effect? Drug Saf 2001; 24: 873-888.
26. Chan KA, Truman A, Gurwitz JH et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med 2003; 163: 728-734.